PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

oleh: J. C. Barrientos, P. M. Barr, A. R. Mato, C. S. Tam, P. Ghia, C. Moreno, N. E. Kay, T. Siddiqi, E. Szafer-Glusman, C. Zhou, L. Neumayr, G. Krigsfeld, W. G. Wierda, T. Shanafelt